Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 15
States / cities: San Diego, California • Whittier, California • Coral Gables, Florida + 11 more

Conditions: Suicide
Interventions: Transdermal Estradiol, Placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Actinic Keratoses
Interventions: Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Fentanyl; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Skin Lesion
Interventions: SkinIO; Device
Lead sponsor: Halcyon Dermatology; Other
Eligibility: 18 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Solid Tumor
Interventions: Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 4 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infection, HIV Infections
Interventions: Efavirenz + Tenofovir DF/Emtricitabine, Raltegravir + Tenofovir DF/Emtricitabine, Colonoscopy with biopsies, Inguinal Lymph Node Excision; Drug · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Hypericin; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pain, Osteoarthritis, Knee
Interventions: Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 5
States / cities: Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more

Conditions: Lung Cancer, Heart Disease, COPD
Interventions: Smoking cessation treatment plus moderate intensity exercise, Smoking cessation treatment plus health education; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pancreas Cancer
Interventions: fine needle aspiration biopsy; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dental Caries
Interventions: Resin infiltration, Sham treatment; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 24 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: West Point, New York

Conditions: Bone Neoplasms
Interventions: Trinity multipotent stem cells, Demineralized bone matrix(DBM); Biological
Lead sponsor: Emory University; Other
Eligibility: 11 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Precancerous Condition
Interventions: Usual care mailing intervention, CIS support mailing intervention; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Angiosarcoma of Skin
Interventions: T-VEC; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Peripheral Arterial Disease
Interventions: Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment, Balloon Angioplasty; Device
Lead sponsor: Cardio Flow, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Gainesville, Florida • Saint Clair Shores, Michigan

Conditions: Endoscopic Submucosal Dissection
Interventions: Endoscopic Submucosal Dissection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida • Boston, Massachusetts • Houston, Texas

Conditions: Post-op Pain
Interventions: Neupro® transdermal patch/placebo; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Peripheral Artery Disease
Interventions: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 39
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 34 more

Conditions: Postherpetic Neuralgia
Interventions: capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more

Conditions: Sleep Related Breathing Disorder, Upper Airway Resistance Syndrome, Obstructive Sleep Apnea
Interventions: Cold ablation inferior turbinate reduction; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: Up to 18 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality

Daylight Photodynamic Therapy for Actinic Keratosis

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Correlation of Dermatologist Made Biopsy Decision With AI Assisted Total Body Photography Detection of Outlier Lesions

Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy

Modifiers of Disease Severity in Cerebral Cavernous Malformations

The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients

Raltegravir Activity In Lymphoid Tissues

Topical SGX302 for Mild-to-Moderate Psoriasis

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?

DNA Microarray Study of Pancreas Cancer

Resin Infiltration to Arrest Early Tooth Decay

Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions

Activating Collaborative CIS Support Via Targeted Provider Mailing

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

Feasibility Clinical Trial of the Cardio Flow Orbital Atherectomy System to Treat Peripheral Artery Disease (PAD)

Multi-center Evaluation of the Clinical Utility of ESD in the Western Population

Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model

ILLUMENATE Pivotal Post-Approval Study (PAS)

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

Inferior Turbinate Reduction in Pediatric Population Failing Surgery for Sleep Disordered Breathing